Global Point of Care
Designed to restore confidence in daily life
The revolutionary NAVICA™ app helps people navigate daily life in a new normal. NAVICA displays results from the 15-minute BinaxNOW™ COVID-19 Ag Card, a rapid antigen test, to help individuals make informed decisions.
This first-of-its-kind app, available at no-charge, allows people who test negative to get an encrypted temporary digital NAVICA Pass, similar to an airline boarding pass. NAVICA-enabled organizations will be able to verify an individual’s negative COVID-19 test results by scanning the individual’s digital NAVICA Pass to facilitate entry into facilities, along with hand-washing, social distancing, enhanced cleaning, and mask-wearing.
The BinaxNOW™ COVID-19 Ag Card test has received U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA).*
Only available in the US.
As a NAVICA-enabled test center, you will use the NAVICA Administrator App to communicate encrypted BinaxNOW COVID-19 Ag Card test results to participants, allowing them to obtain a digital NAVICA Pass with a negative test result.
To conduct testing at your site, a CLIA-waived license is required per the FDA Emergency Use Authorization for BinaxNOW.
Download NAVICA, the first-of-its-kind app, from both the App Store® and Google Play™ store.
Abbott believes the NAVICA app and BinaxNOW COVID-19 Ag Card test will help us recover a bit more freedom, confidence and normalcy in our everyday lives.
Learn more about our contributions to the COVID-19 response and our efforts to attack the pandemic on critical fronts – speed, simplicity, affordability, access and reliability – through the introduction of our innovative BinaxNOW COVID-19 Ag test and NAVICA mobile app.
Learn more about our contributions to the COVID-19 response and our efforts to attack the pandemic on critical fronts – speed, simplicity, affordability, access and reliability – through the introduction of our innovative BinaxNOW COVID-19 Ag test and NAVICA mobile app.
Learn more about our contributions to the COVID-19 response and our efforts to attack the pandemic on critical fronts – speed, simplicity, affordability, access and reliability – through the introduction of our innovative BinaxNOW COVID-19 Ag test and NAVICA mobile app.
| BinaxNOW™ COVID-19 Ag Card | Code |
|---|---|
| BinaxNOW™ COVID-19 Ag Card (40CT) | 195-000 |
| BinaxNOW™ COVID-19 Ag Card Control Kit (10 Positive) | 195-080 |
| COVID-19 Swab Transport Tube Accessory Pack (24 CT) | 190-010 |
NAVICA will display a digital NAVICA Pass via a QR code, similar to an airline boarding pass. This allows organizations to verify negative test results—enabling people to move about with greater confidence.
NAVICA, the first-of-its-kind app, can be downloaded from both the App Store® and Google Play™ at no charge. Go to your app store and search NAVICA and download the blue NAVICA app.
The BinaxNOW COVID-19 Ag Card is a rapid lateral flow antigen test administered by a healthcare professional. It tests for active infection in direct nasal swabs from individuals suspected of COVID-19 by their healthcare provider within the first seven days of symptom onset. It provides a positive or negative result in 15 minutes with no instrument required.
Google Play and the Google Play Logo are trademarks of Google LLC.
App Store and the Apple Logo are trademarks of Apple Inc.
*The BinaxNOW™ COVID-19 Ag Card EUA has not been FDA cleared or approved. It has been authorized by the FDA under an emergency use authorization for use by authorized laboratories and patient care settings. The test has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens, and is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
**Refer to the product package insert for full instructions and clinical data.
† Before testing patients, federal regulations require testing sites to have a CLIA certificate issued by CMS. Sites performing only waived tests must obtain a Certificate of Waiver by applying for this certification for each location performing testing. Learn more about CLIA
A Leader In Rapid Point-of-care Diagnostics.
©2024 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
This website is governed by applicable U.S. laws and governmental regulations. The products and information contained herewith may not be accessible in all countries, and Abbott takes no responsibility for such information which may not comply with local country legal process, regulation, registration and usage.
Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. GDPR Statement
Not all products are available in all regions. Check with your local representative for availability in specific markets. For in vitro diagnostic use only. For i-STAT test cartridge information and intended use, refer to individual product pages or the cartridge information (CTI/IFU) in the i-STAT Support area.
Abbott - A Leader in Rapid Point-of-Care Diagnostics.
